FBR2 can inhibit ferroptosis and cellular senescence induced by BLM through the SIRT3/p53 pathway, potentially involving alterations in the acetylation of p53, thereby treating pulmonary fibrosis (Figure 10). Here, SIRT3 is linked to pulmonary fibrosis.